A Plus Biotech (6918) reported revenue of NT$81.1 million for Oct 2026, +29.8% year on year and +2.0% from the previous month. Revenue for Jan–Oct 2026 was NT$785.6 million (+14.9% year on year).
Year-on-year revenue growth: 10 months in a row. →
In Oct 2026, it ranked No. 86 by revenue among 160 Biotech & Medical companies.
Monthly revenue chart
Hover over (or tap) a bar to see that month’s revenue.
Monthly revenue history
| Month | Revenue | YoY | MoM |
|---|---|---|---|
| Oct 2026 | NT$81.1 million | +29.8% | +2.0% |
| Sep 2026 | NT$79.5 million | +13.4% | +3.8% |
| Aug 2026 | NT$76.6 million | +11.0% | -11.0% |
| Jul 2026 | NT$86 million | +20.1% | +8.6% |
| Jun 2026 | NT$79.2 million | +4.2% | +0.4% |
| May 2026 | NT$78.9 million | +27.2% | -7.1% |
| Apr 2026 | NT$84.9 million | +11.9% | +15.1% |
| Mar 2026 | NT$73.8 million | +16.2% | -0.6% |
| Feb 2026 | NT$74.2 million | +6.5% | +4.0% |
| Jan 2026 | NT$71.4 million | +13.0% | -0.9% |
| Dec 2025 | NT$72 million | -1.5% | -10.4% |
| Nov 2025 | NT$80.4 million | +25.1% | +28.6% |
| Oct 2025 | NT$62.5 million | -7.0% | -10.9% |
| Sep 2025 | NT$70.1 million | +4.9% | +1.6% |
| Aug 2025 | NT$69 million | +2.2% | -3.7% |
| Jul 2025 | NT$71.6 million | +8.6% | -5.8% |
| Jun 2025 | NT$76 million | +24.0% | +22.6% |
| May 2025 | NT$62 million | +5.7% | -18.3% |
| Apr 2025 | NT$75.9 million | +13.5% | +19.5% |
| Mar 2025 | NT$63.5 million | -0.1% | -8.9% |
| Feb 2025 | NT$69.7 million | +30.8% | +10.2% |
| Jan 2025 | NT$63.2 million | +3.4% | -13.5% |
| Dec 2024 | NT$73.1 million | +16.4% | +13.8% |
| Nov 2024 | NT$64.2 million | +11.2% | -4.4% |
| Oct 2024 | NT$67.2 million | +27.8% | +0.5% |
Jan–Oct 2026 cumulative: NT$785.6 million (+14.9% YoY)
Other Biotech & Medical companies
Compare with peers: A Plus Biotech vs PEC / A Plus Biotech vs Lotus Pharm / A Plus Biotech vs Bora
| Company | Revenue | YoY |
|---|---|---|
| PEC | NT$2.84 billion | +102.0% |
| Lotus Pharm | NT$2.13 billion | -22.5% |
| Bora | NT$1.99 billion | +15.9% |
| Great Tree Pharmacy | NT$1.67 billion | +1.5% |
| EXCELSIOR | NT$1.02 billion | +38.6% |
| PEGAVISION | NT$793 million | +13.0% |
| Synmosa Biopharma | NT$766.6 million | +41.2% |
| Y.S.H. | NT$749.4 million | +4.4% |
See also
← All Taiwan listed & OTC companies
Sources: Taiwan Stock Exchange, monthly revenue of listed companies (Government Open Data Platform); Taipei Exchange, monthly revenue of OTC companies (TPEx OpenAPI); historical months from MOPS. Amounts in New Taiwan dollars. Changes calculated by this site from the source figures. Not investment advice. Updated: 2026-11-16